--- title: "Moderna Inc Stock (MRNA) Moved Up by 10.02% on Aug 25: Drivers Behind the Movement" type: "News" locale: "en" url: "https://longbridge.com/en/news/296928530.md" description: "Moderna Inc (MRNA) stock surged 10.02% on Aug 25, outperforming the Pharmaceuticals sector. The rally was driven by positive Wall Street analyst upgrades, strong momentum from Phase 3 oncology trial results for intismeran autogene, and short-covering activity. Despite technical overbought signals and fundamental risks like net losses, institutional investors accumulated shares due to confidence in the company's mRNA cancer pipeline and post-COVID transition." datetime: "2026-08-25T14:16:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296928530.md) - [en](https://longbridge.com/en/news/296928530.md) - [zh-HK](https://longbridge.com/zh-HK/news/296928530.md) generator: "portal-rs" --- # Moderna Inc Stock (MRNA) Moved Up by 10.02% on Aug 25: Drivers Behind the Movement Moderna Inc (MRNA) moved up by 10.02%. The Pharmaceuticals & Medical Research sector is up by 0.51%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Moderna Inc (MRNA) up 10.02%; Eli Lilly and Co (LLY) up 0.32%; Johnson & Johnson (JNJ) up 0.51%. ## What is driving Moderna Inc (MRNA)’s stock price up today? Moderna experienced a strong upward rally driven by a confluence of major Wall Street research upgrades, persistent momentum following historic oncology trial results, and short-covering activity. Analyst sentiment swung decisively positive as sell-side firms significantly raised price targets and long-term financial forecasts. Key brokerages, including Barclays, Wolfe Research, and Bank of America, issued notable target price revisions, citing the multi-billion-dollar commercial potential of the company's personalized mRNA oncology pipeline and solidifying institutional confidence in its post-COVID business transition. The primary fundamental catalyst behind this renewed buying interest remains the landmark Phase 3 INTerpath-001 study results for intismeran autogene, a personalized mRNA cancer vaccine developed in collaboration with Merck. The pivotal trial demonstrated a statistically significant reduction in melanoma recurrence and distant metastasis when combined with Keytruda compared to monotherapy. As the market digested the long-term strategic implications of this first-ever successful Phase 3 readout for an mRNA cancer therapy, institutional investors moved past initial profit-taking to aggressively accumulate shares. Positioning dynamics also played a critical role in accelerating the upward move. Heading into the clinical readout, the stock was among the more heavily shorted large-cap biotech names due to declining COVID-19 vaccine revenues. The decisive Phase 3 success forced widespread short covering while triggering portfolio rebalancing among healthcare funds seeking exposure to novel oncology platforms. Anticipation of pipeline expansion into additional high-value cancer indications, including lung and renal cell carcinomas, further reinforced buy-side conviction. A supportive broader equity backdrop provided additional tailwinds, as risk-on sentiment in growth and biotech sectors complemented the company's positive idiosyncratic updates. With multiple analyst upgrades validating the commercial viability of its oncology division, Moderna continues to undergo a major structural valuation reassessment by the market. ## Technical Analysis of Moderna Inc (MRNA) Technically, Moderna Inc (MRNA) shows a MACD (12,26,9) value of 20.357, indicating a buy signal. The RSI at 71.751 suggests buy condition and the Williams %R at 18.146 suggests overbought condition. Please monitor closely. ## Media Coverage of Moderna Inc (MRNA) In terms of media coverage, Moderna Inc (MRNA) shows a coverage score of 75, indicating a high level of media attention. The overall market sentiment index is currently in extremely bullish zone. ## Fundamental Analysis of Moderna Inc (MRNA) Moderna Inc (MRNA) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $1.94B, ranking 39 in the industry. The net profit is $-2.82B, ranking 195 in the industry. Company Profile Over the past month, multiple analysts have rated the company as Hold, with an average price target of $95.85, a high of $170.00, and a low of $25.00. ## More details about Moderna Inc (MRNA) Company Specific Risks: - **Post-Surge Profit-Taking and Technical Overbought Reversal:** Following a massive multi-session rally triggered by Phase 3 INTerpath-001 trial data, Moderna's stock experienced an abrupt downward reversal—plummeting over 20% across subsequent sessions—as traders locked in rapid gains and unwound historically overbought technical conditions. - **Missing Granular Trial Data and Efficacy Uncertainty:** Institutional analysts noted that the top-line trial release omitted crucial clinical metrics—such as hazard ratios, confidence intervals, p-values, and median follow-up times—creating valuation friction over the exact incremental benefit intismeran adds over standard Keytruda monotherapy. - **Distant Commercialization Timelines and Manufacturing Complexity:** Analyst commentary emphasized that widespread regulatory approvals and commercial revenue generation from personalized cancer immunotherapies remain years away, while scaling bespoke, patient-specific neoantigen manufacturing poses steep operational and margin challenges. - **Persistent Loss Position and High Cash Burn Rate:** Moderna continues to face underlying financial vulnerabilities, underscored by its Q2 GAAP net loss of $782 million, a $950 million litigation settlement payout in July, and projected full-year 2026 cost of sales near $1.7 billion against depressed post-pandemic product revenues. Find out more ### Related Stocks - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md) - [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md) - [BCS.US](https://longbridge.com/en/quote/BCS.US.md) - [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [Moderna Stock (MRNA) Slides 3% on Plans for a $2B Private Placement](https://longbridge.com/en/news/297195128.md) - [Wolfe Research Just Upgraded Moderna Stock. Here's Why.](https://longbridge.com/en/news/296951590.md) - [Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes | MRNA Stock News](https://longbridge.com/en/news/297314560.md) - [This Moderna Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday](https://longbridge.com/en/news/297353340.md) - [Moderna plans private placement of $2 billion convertible senior notes offering](https://longbridge.com/en/news/297176043.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**